Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

Launched by CENTRE ANTOINE LACASSAGNE · Sep 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to identify genetic changes in tumors using a test called liquid biopsy, which analyzes a sample of blood instead of a traditional tissue sample (solid biopsy). This research aims to see how well liquid biopsy can help doctors understand the makeup of tumors in patients with advanced-stage cancer that can't be cured. The study is currently looking for participants who are over 18 years old, speak and understand French, and have a specific type of advanced cancer that has been previously assessed at a special meeting for molecular biology.

If you or a family member are considering joining this study, you should know that participants will need to have certain archived tumor samples available or a tumor that can be biopsied. The trial is open to all genders, and while it aims to help improve cancer diagnostics, it will not accept individuals with other recent cancers or certain health conditions. Participants will be closely monitored and will have the chance to contribute to important research that could benefit future cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years old.
• • Advanced-stage malignant solid tumor managed in a non-curative context.
• • Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
• • Performance status of 0 or 1.
• • Patient able to read, write, and understand the French language.
• • Patient has read the information sheet and signed the informed consent.
• • Patient has social security coverage.
• Exclusion Criteria:
• • Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.
• • Severe or uncontrolled systemic disease.
• • Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.
• * Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:
• • Pregnant women, women in labor, and breastfeeding mothers,
• • Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,
• • Persons admitted to a healthcare or social institution for reasons other than research,
• • Adults unable to give their consent.